J.B. Chemicals & Pharmaceuticals Limited reported a net profit of INR 70,947 Lakhs for the financial year ended March 31, 2026, according to its Business Responsibility and Sustainability Report filed on May 25, 2026. The company achieved consolidated revenue from operations of INR 4,14,779 Lakhs, reflecting steady growth compared to the previous year. The Board of Directors recommended a final dividend of INR 9.30 per equity share for the fiscal year.

The company maintained a strong operational safety record, reporting zero fatalities across all manufacturing plants and locations for the reporting period. JB Pharma also recorded zero Lost Time Injury Frequency Rate (LTIFR) and no cases of occupational disease. The organization spent 0.24% of its total revenue on measures towards the well-being of employees and workers.

Environmental Performance

JB Pharma made significant progress in its environmental sustainability initiatives during FY26. The company substituted over 43% of its total energy consumption with renewable sources, exceeding the previous year's figure of 37%. Total energy consumed stood at 635,119.6 Giga Joules (GJ), with renewable sources accounting for 43.70% of the total energy mix.

The company achieved Zero Liquid Discharge (ZLD) across all manufacturing sites. Total water consumption was recorded at 307,507.11 kiloliters (KL), while water discharge amounted to 4,346.32 KL. JB Pharma reported total Scope 1 emissions of 5,238.92 MT of CO2e and Scope 2 emissions (market-based) of 54,647.26 MT of CO2e.

Waste Management

The company managed a total of 3,276.09 metric tonnes (MT) of waste across its operations. A significant portion of the waste was recovered through recycling and other recovery operations, totaling 2,497.76 MT, which represents 76.24% of the total waste generated. The waste disposed via incineration and landfilling was 580.87 MT.

Social and Governance Metrics

JB Pharma reported a total workforce of 7,906 employees and workers. The gross wages paid to females constituted 10.28% of the total wages paid by the entity. The company confirmed zero complaints regarding sexual harassment (POSH) and zero incidents of discrimination during the year.

DNV Business Assurance India Private Limited provided reasonable assurance for the BRSR Core indicators and limited assurance for the non-financial sustainability disclosures. The assurance covered operations across 8 manufacturing plants, 1 corporate office, 1 registered office, 5 regional offices, 1 R&D centre, 26 C&F locations, and 5 warehouses.

J.B. Chemicals & Pharmaceuticals Limited reported a 6% increase in consolidated revenue to ₹4,148 crore for the financial year ended March 31, 2026. The company’s operating EBITDA grew by 8% to ₹1,178 crore, and profit after tax rose by 8% to ₹709 crore.

The growth was driven by a favourable product mix and stable costs, which supported gross margin expansion. On a consolidated basis, revenue stood at ₹4,14,779 lakhs, registering a 6% year-on-year growth. EBITDA margins improved to 28.4% adjusted for non-recurring items.

The domestic formulations business grew 9% to ₹24,735.4 lakhs, outperforming the Indian Pharmaceutical Market. The international business recorded revenue growth of 2% to ₹16,742.5 lakhs, supported by a healthy order pipeline in the CDMO segment.

Financial Highlights

The board has recommended a final dividend of ₹9.30 per equity share for FY26. The interim dividend of ₹12.70 per share was paid on February 25, 2026.